RCT | Balovaptan no better than placebo for social communication in childhood autism spectrum disorder.
8 Jul, 2022 | 11:38h | UTC
Commentary on Twitter
In this RCT, balovaptan did not demonstrate efficacy in improvement of socialization and communication in pediatric autism spectrum disorder (ASD), highlighting challenges faced in #ASD trial design, such as outcome measure sensitivity & placebo response. https://t.co/FFAJeu5xv0
— JAMA Psychiatry (@JAMAPsych) July 6, 2022